Medical Dialogues4d
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
Clinical Pain Advisor4d
REDEFINE 2: Significant Weight Loss Observed With CagriSema vs Placebo in Patients With T2D
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Endocrinology Advisor6d
Significant Weight Loss Observed With CagriSema in REDEFINE 2 Trial
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Pharmabiz6d
Novo Nordisk announces results from REDEFINE 2 trial of CagriSema in people with obesity and type 2 diabetes
Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
pharmaphorum3d
Novo Nordisk's CagriSema data disappoints investors again
Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...